Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2
Joseph E. KlebbaiD, Nilotpal RoyiD, Steffen M. BernardiD, Stephanie GrabowiD, Melissa A. HoffmaniD, Hui MiaoiD, Junko TamiyaiD, Jinwei WangiD, Cynthia BerryiD, Antonio Esparza-OrosiD, Richard D. LiniD, Yongsheng LiuiD, Marie PariollaudiD, Holly ParkeriD, Igor Mochalkin, Sareena RanaiD, Aaron Nathan SneadiD, Eric WaltoniD, Taylor E. Wyrick, Erick W. AitchisoniD, Karl BedkeiD, Jacyln C. BrannoniD, Joel M. Chick, Kenneth HeeiD, Benjamin D. HorningiD, , Matthew P. PatricelliiD
Abstract
Genetic disruption of the RAS binding domain (RBD) of PI 3-kinase (PI3K) prevents the growth of mutant RAS driven tumors in mice and does not impact PI3Ks role in insulin mediated control of glucose homeostasis. Selectively blocking the RAS-PI3K interaction may represent an attractive strategy for treating RAS-dependent cancers as it would avoid the toxicity associated with inhibitors of PI3K lipid kinase activity such as alpelisib. Here we report compounds that bind covalently to cysteine 242 in the RBD of PI3K p110 and block the ability of RAS to activate PI3K activity. These inhibitors have a profound impact on the growth of RAS mutant and also HER2 over-expressing tumors, particularly when combined with other inhibitors of the RAS/MAPK pathway, without causing hyperglycemia.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 16
- FWCI
- 4.42
- Field percentile
- top 4%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition
Xiangyu Ge, Jaffarguriqbal Singh, … Mandar Deepak Muzumdar·bioRxiv·Jun 20, 2025
- Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition
Katherine Parker, Samar Ghorbanpoor, … Aaron N. Hata·bioRxiv·Apr 30, 2026
- RTK-dependent inducible degradation of mutant PI3K alpha drives GDC-0077 (Inavolisib) efficacy
K. Song, K. Edgar, … L. Friedman·Cancer DiscoveryPeer-reviewed·Sep 20, 2021
- KRAS G12D can be targeted by potent salt-bridge forming inhibitors
- Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector binding
M. J. McCarthy, C. V. Pagba, … A. A. Gorfe·bioRxiv·Oct 11, 2018
- MRTX1133 is a potent non-covalent KRAS (G12C) inhibitor with tissue-specific activity
Abraham C. Sianoya, Yan Zuo, … Alemayehu Abebe Gorfe·Molecular Cancer TherapeuticsPeer-reviewed·Mar 14, 2026